Ghent University Academic Bibliography

Journal Article
A1
open access

Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome

Andrew M Siedlecki, Nicole Isbel, Johan Vande Walle (UGent) , Jennifer James Eggleston, David J Cohen, Christoph Licht, Véronique Frémeaux-Bacchi, Gema Ariceta, Gianluigi Ardissino, Fadi Fakhouri, et al.

(2019) KIDNEY INTERNATIONAL REPORTS. 4(3). p.434-446

Add to list

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome

Franz Schaefer, Gianluigi Ardissino, Gema Ariceta, Fadi Fakhouri, Marie Scully, Nicole Isbel, Åsa Lommelé, Varant Kupelian, Christoph Gasteyger, Larry A. Greenbaum, et al.

(2018) KIDNEY INTERNATIONAL. 94(2). p.408-418

Add to list

Conference Paper
C3
open access

Atypical haemolytic uraemic syndrome (aHUS) in children and adults: data from the Global aHUS Registry

Sally Johnson, Christoph Licht, Gianluigi Ardissimo, Gema Ariceta, David J Cohen, Christoph Gasteyger, Larry A Greenbaum, Masayo Ogawa, Varant Kupelian, Franz Schaefer, et al.

(2016) UK Kidney Week, Abstracts.

Add to list

Journal Article
A1
open access

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Larry A Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I Al-Akash, Jonathan Evans, Paul Henning, Kenneth V Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, et al.

(2016) KIDNEY INTERNATIONAL. 89(3). p.701-711

Add to list

Manifestations of atypical haemolytic uraemic syndrome (AHUS) in children and adults : data from the global registry

Franz Schaefer, Christophe Licht, Gianluigi Ardissino, Gema Ariceta, Varant Kupelian, Christoph Gasteyger, Larry A Greenbaum, Masayo Ogawa, Johan Vande Walle (UGent) and Veronique Fremaux-bacchi

(2015) PEDIATRIC NEPHROLOGY. 30(9). p.1544-1544

Add to list

Journal Article
A1
open access

The global aHUS registry : methodology and initial patient characteristics

Christoph Licht, Gianluigi Ardissino, Gema Ariceta, David Cohen, J Alexander Cole, Christoph Gasteyger, Larry A Greenbaum, Sally Johnson, Masayo Ogawa, Franz Schaefer, et al.

(2015) BMC NEPHROLOGY. 16.

Add to list

A prospective study of paediatric patients with atypical haemolytic uraemic syndrom (aHUS) treated with eculuzumab : 1- year update

Lesley Reece, Larry A Greenbaum, Marc Fila, Gianluigi Ardissimo, Samhar Al-akash, Jonathan Evans, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Nicole Van de Kar, et al.

(2015) PEDIATRIC NEPHROLOGY. 30(9). p.1564-1564

Add to list

Conference Paper
C3
open access

Safety and efficacy of eculizumab in pediatric patients with aHUS, with or without baseline dialysis

Johan Vande Walle (UGent) , Larry A Greenbaum, Camille L Bedrosian, Masayo Ogawa, John F Kincaid and Chantal Loirat

(2014) Kidney Week, Abstracts.

Add to list

Conference Paper
C3
open access

An observational, non-interventional, multinational registry of patients with atypical haemolytic uraemic syndrome: initial patient chracteristics

Franz Schaefer, Véronique Frémeaux-Bacchi, Gema Ariceta, Masayo Ogawa, Johan Vande Walle (UGent) and Christoph Licht

(2014) Paediatric Nephrology, Joint meeting of GPN and WGPN CPS, Abstracts.

Add to list

Conference Paper
C3
open access

Safety and efficacy of eculizumab in pediatrics patients with aHUS, with or without baseline dialysis

Johan Vande Walle (UGent) , Larry A Greenbaum, Camille L Bedrosian, Masayo Ogawa, John F Kincaid and Chantal Loirat

(2014) ERA-EDTA, 51st Congress, Abstracts.

Add to list

Conference Paper
C3
open access

Baseline demographics and characteristics of 532 patients with atypical hemolytic uremic syndrome in the global aHUS registry

Christoph Licht, Gianluigi Ardissimo, Gema Ariceta, David Cohen, Christoph Gasteyger, Larry A Greenbaum, Masayo Ogawa, Franz Schaefer, Johan Vande Walle (UGent) and Véronique Frémeaux-Bacchi

(2014) American Society of Hematology, 56th Annual meeting, Abstracts.

Add to list

Conference Paper
C3
open access

Increased understanding of atypical haemolytic uraemic syndrome (aHUS): characteristics of patients recruited into the global aHUS registry

Johan Vande Walle (UGent) , Sally Johnson, Véronique Frémeaux-Bacchi, Gianluigi Ardissimo, Gema Ariceta, David Cohen, Larry A Greenbaum, Masayo Ogawa, Franz Schaefer and Christoph Licht

(2014) ERA-EDTA, 51st Congress, Abstracts.

Add to list

Conference Paper
C3
open access

An observational, non-interventional, multicenter, multinational registry of patients with atypical hemolytic uremic syndrome: initial patient characteristics

Christoph Licht, Gianluigi Ardissino, Gema Ariceta, Jon Beauchamp, David Cohen, Larry A Greenbaum, Sally Johnson, Masayo Ogawa, Franz Schaefer, Johan Vande Walle (UGent) , et al.

(2013) ASN Kidney Week, Abstracts.

Add to list

Conference Paper
C3
open access

Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric patients (Pts) with atypical hemolytic uremic syndrome (aHUS)

Larry A Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I Al-Akash, Jonathan Evans, Paul Henning, Kenneth V Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, et al.

(2013) BLOOD. 122(21).

Add to list

Conference Paper
C3
open access

Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric patients with atypical hemolytic uremic syndrome

Larry Greenbaum, Marc Fila, Michel Tsimaratos, Gianluigi Ardissimo, Samhar I Al-Akash, Jonathan Evans, Paul Henning, Kenneth V Lieberman, Silvio Maringhini, Lars Pape, et al.

(2013) ASN Kidney Week, Abstracts.

Academic Bibliography

Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome

Atypical haemolytic uraemic syndrome (aHUS) in children and adults: data from the Global aHUS Registry

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Manifestations of atypical haemolytic uraemic syndrome (AHUS) in children and adults : data from the global registry

The global aHUS registry : methodology and initial patient characteristics

A prospective study of paediatric patients with atypical haemolytic uraemic syndrom (aHUS) treated with eculuzumab : 1- year update

Safety and efficacy of eculizumab in pediatric patients with aHUS, with or without baseline dialysis

An observational, non-interventional, multinational registry of patients with atypical haemolytic uraemic syndrome: initial patient chracteristics

Safety and efficacy of eculizumab in pediatrics patients with aHUS, with or without baseline dialysis

Baseline demographics and characteristics of 532 patients with atypical hemolytic uremic syndrome in the global aHUS registry

Increased understanding of atypical haemolytic uraemic syndrome (aHUS): characteristics of patients recruited into the global aHUS registry

An observational, non-interventional, multicenter, multinational registry of patients with atypical hemolytic uremic syndrome: initial patient characteristics

Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric patients (Pts) with atypical hemolytic uremic syndrome (aHUS)

Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric patients with atypical hemolytic uremic syndrome

Contents

Support

Contact